Production of radioisotopes for nuclear medicine using ion-beam technology and its utilization for both therapeutic and diagnostic application in cancer
飯田 靖彦*; 花岡 宏史*; 渡辺 智; 渡邉 茂樹; 石岡 典子; 吉岡 弘樹*; 山元 進司*; Paudyal, P.*; Paudyal, B.*; 樋口 哲也*; 織内 昇*; 遠藤 啓吾*
Iida, Yasuhiko*; Hanaoka, Hirofumi*; Watanabe, Satoshi; Watanabe, Shigeki; Ishioka, Noriko; Yoshioka, Hiroki*; Yamamoto, Shinji*; Paudyal, P.*; Paudyal, B.*; Higuchi, Tetsuya*; Oriuchi, Noboru*; Endo, Keigo*
As antibody binds specifically to corresponding antigens, radiolabeled antibody also binds to cells expressing antigens on surface membranes. Large amounts of antibodies labeled with cytotoxic radionuclides are administered intravenously in cancer patients, after diagnostic imaging using the tracer amount of radiolabeled antibody. In this study, we developed this therapy, called radioimmunotherapy, for effective treatment in cancer patients without damaging normal cells which do not express antigens. We developed Lu-DOTA-NuB2 using carrier-free Lu, and obtained remarkable results for decreasing tumor. Tumor specific radionuclide therapy using Lu is effective therapy with less adverse reactions.